Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded access programme of ICP-NI (CV-15) for Corona 19 in the United States

Trial Profile

Expanded access programme of ICP-NI (CV-15) for Corona 19 in the United States

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CV 15 (Primary)
  • Indications COVID 2019 infections
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 19 Oct 2020 According to a Cellivery media release, all researchers and executives are working with desperate determination to apply for an upcoming US FDA IND.
  • 19 Oct 2020 According to a Cellivery media release, based on the evaluation results provided by COVANC, the company announced that this data is sufficient to apply for a clinical trial plan with the U.S. Food and Drug Administration (FDA) and is planning to enter in this trial without additional primate test.
  • 28 Aug 2020 According to a Cellivery media release, the company complete all safety and therapeutic efficacy evaluation tests as soon as possible and initiate this study in the fourth quarter of this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top